# Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

> **NCT07747740** · PHASE2 · RECRUITING · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 228 (estimated)

## Conditions studied

- Non-Muscle-Invasive Bladder Cancer
- BCG-Unresponsive Bladder Cancer

## Interventions

- **DRUG:** Gemcitabin
- **DRUG:** Docetaxel
- **DRUG:** Mitomicin C

## Key facts

- **NCT ID:** NCT07747740
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747740, "Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07747740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*